{"protocolSection": {"identificationModule": {"nctId": "NCT03688074", "orgStudyIdInfo": {"id": "D5180C00013"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)", "officialTitle": "A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults With Inadequately Controlled Asthma on Inhaled Corticosteroids and at Least One Additional Asthma Controller (CASCADE)", "acronym": "CASCADE"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "startDateStruct": {"date": "2018-11-02", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-11-16", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-11-16", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-09-26", "studyFirstSubmitQcDate": "2018-09-26", "studyFirstPostDateStruct": {"date": "2018-09-28", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-11-12", "resultsFirstSubmitQcDate": "2022-02-18", "resultsFirstPostDateStruct": {"date": "2022-02-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-02-18", "lastUpdatePostDateStruct": {"date": "2022-02-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Amgen", "class": "INDUSTRY"}]}, "oversightModule": {"isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.", "detailedDescription": "This is a multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled moderate-to-severe asthma, taking inhaled corticosteroids and at least one additional asthma controller. Approximately 110 subjects will be randomized globally. Subjects will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 28-week treatment period. Although, due to the Covid-19 pandemic this may be an extended time frame for some subject visits. The study also includes a post-treatment follow-up period of 12 weeks."}, "conditionsModule": {"conditions": ["Asthma", "Bronchial Diseases", "Respiratory Tract Diseases", "Lung Diseases, Obstructive", "Lung Diseases", "Respiratory Hypersensitivity", "Hypersensitivity, Immediate", "Hypersensitivity", "Immune System Diseases"], "keywords": ["Asthma", "Uncontrolled asthma", "Severe uncontrolled asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Subjects will be randomized in a 1:1 ratio to either tezepelumab or matching placebo both administered subcutaneously.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "maskingDescription": "Double-blind", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 116, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Tezepelumab", "type": "EXPERIMENTAL", "description": "Tezepelumab subcutaneous injection", "interventionNames": ["Biological: Tezepelumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo subcutaneous injection", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Tezepelumab", "description": "Tezepelumab subcutaneous injection", "armGroupLabels": ["Tezepelumab"]}, {"type": "OTHER", "name": "Placebo", "description": "Placebo subcutaneous injection", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Airway Submucosal Inflammatory Cells Ratio Change From Baseline to EOT.", "description": "The change from baseline to end of treatment (EOT) expressed as a ratio i.e. (EOT/baseline) in numbers of each of the airway submucosal inflammatory cells, determined by microscopic evaluation of bronchoscopic biopsies.", "timeFrame": "First dose of investigational product to end of treatment (EOT) at Week 28 (or up to Week 48 due to COVID19 pandemic)."}], "secondaryOutcomes": [{"measure": "Reticular Basement Membrane (RBM) Thickness Ratio Change From Baseline to EOT.", "description": "The change from baseline to EOT expressed as a ratio i.e. (EOT/baseline) in RBM thickness, determined by microscopic evaluation of bronchoscopic biopsies.", "timeFrame": "First dose of investigational product to end of treatment (EOT) at Week 28 (or up to Week 48 due to COVID19 pandemic)."}, {"measure": "Percent (%) Airway Epithelial Integrity Ratio Change From Baseline to EOT.", "description": "The change from baseline to EOT expressed as a ratio i.e. (EOT/baseline) in % airway epithelial, determined by microscopic evaluation of bronchoscopic biopsies.", "timeFrame": "First dose of investigational product to end of treatment (EOT) at Week 28 (or up to Week 48 due to COVID19 pandemic)."}]}, "eligibilityModule": {"eligibilityCriteria": "Principal Inclusion Criteria:\n\n* Subject must be 18 to 75 years of age.\n* Documented physician-diagnosed asthma for at least 12 months.\n* Subjects who have received a physician- prescribed asthma controller medication with medium or high dose ICS for at least 12 months; must be stable for at least 3 months prior to screening visit.\n* At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.\n* At enrolment, the subject must have a predicted normal value for the morning pre-bronchodilator FEV1\\>50% and more than 1L.\n* Evidence of asthma as documented by reversibility of FEV1 \u226512% and \u2265200 mL in the previous 12 months prior to screening, or during the screening period prior to randomization.\n* ACQ-6 score \u2265 1.5 during the screening period prior to randomization.\n\nPrincipal Exclusion Criteria:\n\n* Any clinically important pulmonary disease other than asthma.\n* History of cancer.\n* Hospitalization or required OCS for asthma exacerbation within 6 weeks of enrolment or \\>3 exacerbations requiring OCS or hospitalization in the year prior to visit 1 or who had been intubated or admitted to ICU for asthma exacerbation in the year prior to enrolment.\n* History of a clinically significant infection, including upper (URTI) or lower respiratory tract infection (LRTI), requiring treatment with antibiotics or antiviral medications finalized \\<2 weeks before visit 1 or during the run-in period.\n* Current smokers or subjects with smoking history \u226510 pack-yrs, including e-cigarettes. Former smokers with a smoking history of \\<10 pack-yrs must have stopped for at least 6 months prior to visit 1, including e-cigarette use.\n* History of chronic alcohol or drug abuse within 12 months prior to visit 1.\n* Tuberculosis requiring treatment within 12 months prior to visit 1.\n* History of known immunodeficiency disorder including a positive HIV test at visit 1, or the subject is taking antiretroviral medications as determined by medical history and/or subject's verbal report.\n* History of anaphylaxis or documented immune complex disease (type III hypersensitivity reactions) following any biologic therapy Subject randomized in a previous Tezepelumab study or in a current study with another investigational product.\n* Pregnant, breastfeeding or lactating women.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Chris Brightling", "affiliation": "University of Leicester, United Kingdom", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Research Site", "city": "New Haven", "state": "Connecticut", "zip": "06510", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Research Site", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Research Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Research Site", "city": "Galveston", "state": "Texas", "zip": "77555", "country": "United States", "geoPoint": {"lat": 29.30135, "lon": -94.7977}}, {"facility": "Research Site", "city": "Calgary", "state": "Alberta", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "zip": "L8N 3Z5", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "zip": "K1H 8L6", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H4A 3J1", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Aarhus N", "zip": "8200", "country": "Denmark", "geoPoint": {"lat": 56.15674, "lon": 10.21076}}, {"facility": "Research Site", "city": "Hvidovre", "zip": "2650", "country": "Denmark", "geoPoint": {"lat": 55.65719, "lon": 12.47364}}, {"facility": "Research Site", "city": "K\u00f8benhavn NV", "zip": "2400", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Research Site", "city": "Naestved", "zip": "4700", "country": "Denmark", "geoPoint": {"lat": 55.22992, "lon": 11.76092}}, {"facility": "Research Site", "city": "Odense C", "zip": "5000", "country": "Denmark", "geoPoint": {"lat": 55.39594, "lon": 10.38831}}, {"facility": "Research Site", "city": "Vejle", "zip": "7100", "country": "Denmark", "geoPoint": {"lat": 55.70927, "lon": 9.5357}}, {"facility": "Research Site", "city": "\u00c5lborg", "zip": "9000", "country": "Denmark"}, {"facility": "Research Site", "city": "Frankfurt/Main", "zip": "60389", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Grosshansdorf", "zip": "22927", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "Research Site", "city": "Landsberg", "zip": "86899", "country": "Germany", "geoPoint": {"lat": 51.52698, "lon": 12.16076}}, {"facility": "Research Site", "city": "Cambridge", "zip": "CB2 0QQ", "country": "United Kingdom", "geoPoint": {"lat": 52.2, "lon": 0.11667}}, {"facility": "Research Site", "city": "Headington", "zip": "OX3 9DU", "country": "United Kingdom", "geoPoint": {"lat": 51.75737, "lon": -1.21974}}, {"facility": "Research Site", "city": "Leicester", "zip": "LE3 9QP", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "Research Site", "city": "London", "zip": "W1G 8HU", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Research Site", "city": "Nottingham", "zip": "NG5 1PB", "country": "United Kingdom", "geoPoint": {"lat": 52.9536, "lon": -1.15047}}, {"facility": "Research Site", "city": "Wythenshawe", "zip": "M23 9QZ", "country": "United Kingdom", "geoPoint": {"lat": 53.38027, "lon": -2.2654}}]}, "referencesModule": {"references": [{"pmid": "34403803", "type": "DERIVED", "citation": "Pham TH, Chen C, Colice G, Parnes JR, Griffiths JM, Cook B. Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2021 Dec;127(6):689-691. doi: 10.1016/j.anai.2021.08.008. Epub 2021 Aug 14. No abstract available."}, {"pmid": "34256031", "type": "DERIVED", "citation": "Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, Johnston J, Molfino N, Parnes JR, Megally A, Colice G, Brightling CE; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Nov;9(11):1299-1312. doi: 10.1016/S2213-2600(21)00226-5. Epub 2021 Jul 10. Erratum In: Lancet Respir Med. 2021 Nov;9(11):e106."}, {"pmid": "33050900", "type": "DERIVED", "citation": "Emson C, Diver S, Chachi L, Megally A, Small C, Downie J, Parnes JR, Bowen K, Colice G, Brightling CE. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma. Respir Res. 2020 Oct 13;21(1):265. doi: 10.1186/s12931-020-01513-x."}], "seeAlsoLinks": [{"label": "Statistical Analysis Plan (SAP)", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00013&amp;attachmentIdentifier=2a6dc7e6-ac84-4c9c-82fd-052e2347fc8f&amp;fileName=d5180c00013-sap-ed-3-redacted.pdf&amp;versionIdentifier="}, {"label": "CSP", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00013&amp;attachmentIdentifier=e9e53dab-6b0a-4841-89a1-9e49fc805541&amp;fileName=d5180c00013-csp-v4-redacted.pdf&amp;versionIdentifier="}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study randomized subjects across the spectrum of T2 status. Randomization was stratified by screening blood eosinophil level (\\<150 , 150 - \\<300, \\>=300 cells/\u00b5L).", "recruitmentDetails": "116 subjects randomized to Tezepelumab 210 mg Q4W or Placebo in 1:1 treatment allocation. All randomized subjects were treated.", "groups": [{"id": "FG000", "title": "Teze 210 mg Q4W", "description": "Tezepelumab subcutaneous injection"}, {"id": "FG001", "title": "Placebo", "description": "Placebo subcutaneous injection"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "59"}, {"groupId": "FG001", "numSubjects": "57"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "58"}, {"groupId": "FG001", "numSubjects": "56"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full Analysis Set - Include all subjects randomised to study treatment who received at least one dose of IP, irrespective of their protocol adherence and continued participation in the study.", "groups": [{"id": "BG000", "title": "Teze 210 mg Q4W", "description": "Tezepelumab subcutaneous injection"}, {"id": "BG001", "title": "Placebo", "description": "Placebo subcutaneous injection"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "116"}]}], "measures": [{"title": "Age, Categorical", "description": "Full Analysis Set - Include all subjects randomised to study treatment who received at least one dose of IP, irrespective of their protocol adherence and continued participation in the study.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "49"}, {"groupId": "BG002", "value": "100"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "16"}]}]}]}, {"title": "Age, Continuous", "description": "Full Analysis Set - Include all subjects randomised to study treatment who received at least one dose of IP, irrespective of their protocol adherence and continued participation in the study.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "50.4", "spread": "12.7"}, {"groupId": "BG001", "value": "50.4", "spread": "13.9"}, {"groupId": "BG002", "value": "50.4", "spread": "13.2"}]}]}]}, {"title": "Sex: Female, Male", "description": "Full Analysis Set - Include all subjects randomised to study treatment who received at least one dose of IP, irrespective of their protocol adherence and continued participation in the study.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "65"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "51"}]}]}]}, {"title": "Race/Ethnicity, Customized", "description": "Race - Full Analysis Set - Include all subjects randomised to study treatment who received at least one dose of IP, irrespective of their protocol adherence and continued participation in the study.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "109"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Other (includes Native Hawaiian or Other Pacific Islander and American Indian or Alaska Native)", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Race/Ethnicity, Customized", "description": "Ethnicity - Full Analysis Set - Include all subjects randomised to study treatment who received at least one dose of IP, irrespective of their protocol adherence and continued participation in the study.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "116"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Airway Submucosal Inflammatory Cells Ratio Change From Baseline to EOT.", "description": "The change from baseline to end of treatment (EOT) expressed as a ratio i.e. (EOT/baseline) in numbers of each of the airway submucosal inflammatory cells, determined by microscopic evaluation of bronchoscopic biopsies.", "populationDescription": "Number of Participants Analyzed are all subjects randomized to study treatment who completed at least 20 weeks of study treatment and had an EOT visit not greater than 8 weeks after date of last dose of IP. In order to be included in analysis, the participants also had to have a non-missing baseline as well as a non-missing EOT assessment for the respective variable.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "First dose of investigational product to end of treatment (EOT) at Week 28 (or up to Week 48 due to COVID19 pandemic).", "groups": [{"id": "OG000", "title": "Teze 210 mg Q4W", "description": "Tezepelumab subcutaneous injection"}, {"id": "OG001", "title": "Placebo", "description": "Placebo subcutaneous injection"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "56"}]}], "classes": [{"title": "Eosinophils", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "lowerLimit": "0.06", "upperLimit": "0.21"}, {"groupId": "OG001", "value": "0.75", "lowerLimit": "0.41", "upperLimit": "1.38"}]}]}, {"title": "Neutrophils", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.11", "lowerLimit": "0.88", "upperLimit": "1.39"}, {"groupId": "OG001", "value": "0.81", "lowerLimit": "0.66", "upperLimit": "1.01"}]}]}, {"title": "T cells CD3+", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.91", "lowerLimit": "0.78", "upperLimit": "1.07"}, {"groupId": "OG001", "value": "0.81", "lowerLimit": "0.70", "upperLimit": "0.95"}]}]}, {"title": "T cells CD4+", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.96", "lowerLimit": "0.82", "upperLimit": "1.14"}, {"groupId": "OG001", "value": "0.81", "lowerLimit": "0.70", "upperLimit": "0.95"}]}]}, {"title": "Mast cells Tryptase+", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.84", "lowerLimit": "0.70", "upperLimit": "1.02"}, {"groupId": "OG001", "value": "1.01", "lowerLimit": "0.84", "upperLimit": "1.22"}]}]}, {"title": "Mast cells Chymase+", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "51"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.07", "lowerLimit": "0.76", "upperLimit": "1.52"}, {"groupId": "OG001", "value": "0.90", "lowerLimit": "0.65", "upperLimit": "1.26"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "Nominal p-values were reported. No adjustment of multiplicity was performed.", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment+log transformed baseline value+stratification factor (screening eos count \\[\\<150, 150-\\<300, \\>=300 cells/uL\\])", "paramType": "Ratio of Geometric LSMeans", "paramValue": "0.15", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.06", "ciUpperLimit": "0.35", "estimateComment": "Parameter : Eosinophils (cells/mm\\^2)", "otherAnalysisDescription": "95% CI (0.05, 0.41)"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.106", "pValueComment": "Nominal p-values were reported. No adjustment of multiplicity was performed.", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment+log transformed baseline value+stratification factor (screening eos count \\[\\<150, 150-\\<300, \\>=300 cells/uL\\])", "paramType": "Ratio of Geometric LSMeans", "paramValue": "1.36", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.99", "ciUpperLimit": "1.86", "estimateComment": "Parameter: Neutrophils (cells/mm\\^2)", "otherAnalysisDescription": "95% CI (0.94, 1.97)"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.389", "pValueComment": "Nominal p-values were reported. No adjustment of multiplicity was performed.", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment+log transformed baseline value+stratification factor (screening eos count \\[\\<150, 150-\\<300, \\>=300 cells/uL\\])", "paramType": "Ratio of Geometric LSMeans", "paramValue": "1.12", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.90", "ciUpperLimit": "1.40", "estimateComment": "Parameter: T cells CD3+ (cells/mm\\^2)", "otherAnalysisDescription": "95% CI (0.86, 1.46)"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.216", "pValueComment": "Nominal p-values were reported. No adjustment of multiplicity was performed.", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment+log transformed baseline value+stratification factor (screening eos count \\[\\<150, 150-\\<300, \\>=300 cells/uL\\])", "paramType": "Ratio of Geometric LSMeans", "paramValue": "1.18", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.94", "ciUpperLimit": "1.48", "estimateComment": "Parameter: T cells CD4+ (cells/mm\\^2)", "otherAnalysisDescription": "95% CI (0.90, 1.55)"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.260", "pValueComment": "Nominal p-values were reported. No adjustment of multiplicity was performed.", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment+log transformed baseline value+stratification factor (screening eos count \\[\\<150, 150-\\<300, \\>=300 cells/uL\\])", "paramType": "Ratio of Geometric LSMeans", "paramValue": "0.83", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.64", "ciUpperLimit": "1.09", "estimateComment": "Parameter: Mast cells Tryptase+ (cells/mm\\^2)", "otherAnalysisDescription": "95% CI (0.61, 1.15)"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.546", "pValueComment": "Nominal p-values were reported. No adjustment of multiplicity was performed.", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment+log transformed baseline value+stratification factor (screening eos count \\[\\<150, 150-\\<300, \\>=300 cells/uL\\])", "paramType": "Ratio of Geometric LSMeans", "paramValue": "1.19", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.74", "ciUpperLimit": "1.92", "estimateComment": "Parameter: Mast cells Chymase+ (cells/mm\\^2)", "otherAnalysisDescription": "95% CI (0.67, 2.10)"}]}, {"type": "SECONDARY", "title": "Reticular Basement Membrane (RBM) Thickness Ratio Change From Baseline to EOT.", "description": "The change from baseline to EOT expressed as a ratio i.e. (EOT/baseline) in RBM thickness, determined by microscopic evaluation of bronchoscopic biopsies.", "populationDescription": "All subjects randomised to study treatment who completed at least 20 weeks of study treatment and had a baseline assessment and an EOT assessment not greater than 8 weeks after date of last dose of IP.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "First dose of investigational product to end of treatment (EOT) at Week 28 (or up to Week 48 due to COVID19 pandemic).", "groups": [{"id": "OG000", "title": "Teze 210 mg Q4W", "description": "Tezepelumab subcutaneous injection"}, {"id": "OG001", "title": "Placebo", "description": "Placebo subcutaneous injection"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.87", "lowerLimit": "0.79", "upperLimit": "0.95"}, {"groupId": "OG001", "value": "0.90", "lowerLimit": "0.81", "upperLimit": "0.99"}]}]}]}, {"type": "SECONDARY", "title": "Percent (%) Airway Epithelial Integrity Ratio Change From Baseline to EOT.", "description": "The change from baseline to EOT expressed as a ratio i.e. (EOT/baseline) in % airway epithelial, determined by microscopic evaluation of bronchoscopic biopsies.", "populationDescription": "Number of Participants Analyzed are all subjects randomized to study treatment who completed at least 20 weeks of study treatment and had an EOT visit not greater than 8 weeks after date of last dose of IP. In order to be included in analysis, the participants also had to have a non-missing baseline as well as a non-missing EOT assessment for the respective variable.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "First dose of investigational product to end of treatment (EOT) at Week 28 (or up to Week 48 due to COVID19 pandemic).", "groups": [{"id": "OG000", "title": "Teze 210 mg Q4W", "description": "Tezepelumab subcutaneous injection"}, {"id": "OG001", "title": "Placebo", "description": "Placebo subcutaneous injection"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "56"}]}], "classes": [{"title": "Intact epithelium", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.87", "lowerLimit": "0.61", "upperLimit": "1.23"}, {"groupId": "OG001", "value": "0.84", "lowerLimit": "0.59", "upperLimit": "1.19"}]}]}, {"title": "Damaged epithelium", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.01", "lowerLimit": "0.92", "upperLimit": "1.12"}, {"groupId": "OG001", "value": "0.95", "lowerLimit": "0.86", "upperLimit": "1.04"}]}]}, {"title": "Denuded epithelium", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.05", "lowerLimit": "0.83", "upperLimit": "1.31"}, {"groupId": "OG001", "value": "1.34", "lowerLimit": "1.07", "upperLimit": "1.68"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "From first dose of investigational product to end of treatment (EOT) at Week 28 (or up to Week 48 due to COVID19 pandemic).", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo subcutaneous injection", "deathsNumAffected": 0, "deathsNumAtRisk": 57, "seriousNumAffected": 7, "seriousNumAtRisk": 57, "otherNumAffected": 45, "otherNumAtRisk": 57}, {"id": "EG001", "title": "Teze 210 mg Q4W", "description": "Tezepelumab subcutaneous injection", "deathsNumAffected": 0, "deathsNumAtRisk": 59, "seriousNumAffected": 3, "seriousNumAtRisk": 59, "otherNumAffected": 48, "otherNumAtRisk": 59}], "seriousEvents": [{"term": "Myocarditis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}]}, {"term": "Hiatus hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}]}, {"term": "Post procedural complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}]}, {"term": "Meningioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}]}, {"term": "Squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}]}], "otherEvents": [{"term": "Dry eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 59}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 14, "numAffected": 5, "numAtRisk": 59}]}, {"term": "Injection site granuloma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Injection site pruritus", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 59}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Candida infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}]}, {"term": "Conjunctivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Lower respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 22, "numAffected": 21, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 28, "numAffected": 22, "numAtRisk": 59}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 4, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 59}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 5, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 4, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Post procedural complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 10, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 59}]}, {"term": "Post procedural fever", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 59}]}, {"term": "Procedural pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 9, "numAffected": 6, "numAtRisk": 59}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 9, "numAffected": 6, "numAtRisk": 59}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 59}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 57}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "Globall Clinical Head", "organization": "AstraZeneca", "email": "information.center@astrazeneca.com", "phone": "+1 877-240-9479"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-04-30", "uploadDate": "2021-11-12T14:32", "filename": "Prot_000.pdf", "size": 1260234}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-11-15", "uploadDate": "2021-11-12T14:32", "filename": "SAP_001.pdf", "size": 1952051}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-12-10", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000007249", "term": "Inflammation"}], "ancestors": [{"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "asFound": "Respiratory Tract Diseases", "relevance": "HIGH"}, {"id": "M10293", "name": "Inflammation", "asFound": "Inflammation", "relevance": "HIGH"}, {"id": "M11168", "name": "Lung Diseases", "asFound": "Lung Disease", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "asFound": "Hypersensitivity", "relevance": "HIGH"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "asFound": "Lung Diseases, Obstructive", "relevance": "HIGH"}, {"id": "M10200", "name": "Immune System Diseases", "asFound": "Immune System Diseases", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "asFound": "Bronchial Diseases", "relevance": "HIGH"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "asFound": "Respiratory Hypersensitivity", "relevance": "HIGH"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "asFound": "Hypersensitivity, Immediate", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}